Figure 1
The Effects of Mammary Tumors on Body Mass and the Peripheral Cytokine Response Are Cell Line Specific. (A) Change in body mass between date of tumor inoculation (DOI) and date of euthanasia (DOE) accounting for tumor mass (TTB) for vehicle and each cell line ((DOE-DOI)-TTB); only mice with 4T1 tumors had significant body mass loss relative to the vehicle controls. (B) Total tumor burden in grams, and as a percentage of body mass, did not differ between cell lines. (C) Protein cytokine concentrations of IL-1β, IL-6, and TNF-α were elevated in 4T07 and 4T1 tumors relative to 67NR tumors. CXCL1 was elevated in 4T07 tumors relative to 67NR and 4T1 tumors. (D) Spleen mass was elevated among mice with 4T07 and 4T1 tumors relative to 67NR tumors and vehicle treated mice. (E–I) Spleen mRNA expression expressed as fold change from vehicles. (E) Macrophage marker CD11b was elevated in 4T07 and 4T1 tumors relative to vehicles and 67NR tumors. (F and G) Spleen IL-1β and IL-6 mRNA did not differ between groups. (H) TNFα mRNA expression was significantly reduced in all cell lines relative to vehicles.(I) IL-10 expression was significantly reduced in 4T07 and 4T1 tumors relative to 67NR tumors and vehicles. The measures and tissues were collected 20 days after tumor cell or vehicle inoculation (n = 12–15/group). The data are presented as mean + SEM. Graph bars that do not share a letter are statistically significant different at p < 0.05.
